{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:25:26Z","timestamp":1793057126629,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jclinepi.2020.04.025","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T12:42:15Z","timestamp":1589373735000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"special_numbering":"C","title":["An overview of platform trials with a checklist for clinical readers"],"prefix":"10.1016","volume":"125","author":[{"given":"Jay J.H.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Harari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Dron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Thorlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2020.04.025_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib2","doi-asserted-by":"crossref","first-page":"100406","DOI":"10.1016\/j.conctc.2019.100406","article-title":"Reporting of master protocols towards a standardized approach: a systematic review","volume":"15","author":"Siden","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1745-6215-10-39","article-title":"Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial","volume":"10","author":"Sydes","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib7","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djn267","article-title":"Speeding up the evaluation of new agents in cancer","volume":"100","author":"Parmar","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1740774517725697","article-title":"Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols","volume":"14","author":"Parmar","year":"2017","journal-title":"Clin Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib9","doi-asserted-by":"crossref","first-page":"f2914","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(14)61122-3","article-title":"More multiarm randomised trials of superiority are needed","volume":"384","author":"Parmar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib11","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2016.70.1169","article-title":"Designing clinical trials that accept new arms: an example in metastatic breast cancer","volume":"35","author":"Ventz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib12","series-title":"Center for Drug Evaluation and Research (CDER) CfBEaRC, and Oncology Center of Excellence (OCE)","article-title":"U.S. department of health and human services food and drug administration. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry (draft guidance)","year":"2018"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00046-2018","article-title":"A trial like ALIC(4)E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?","volume":"4","author":"Butler","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","article-title":"Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial","volume":"13","author":"James","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1464-410X.2008.08034.x","article-title":"Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial","volume":"103","author":"James","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib19","first-page":"1696","article-title":"Abiraterone in metastatic prostate cancer","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-12-S1-A3","article-title":"Flexible trial design in practice - dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial","volume":"12","author":"Sydes","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/clpt.2009.68","article-title":"I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy","volume":"86","author":"Barker","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1513750","article-title":"Adaptive randomization of neratinib in early breast cancer","volume":"375","author":"Park","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive randomization of veliparib-carboplatin treatment in breast cancer","volume":"375","author":"Rugo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13063-019-3216-8","article-title":"This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols","volume":"20","author":"Schiavone","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13063-019-3322-7","article-title":"Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons","volume":"20","author":"Hague","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib31","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple comparison procedure for comparing several\u00a0treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1740774515621721","article-title":"A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: a model for pandemic response","volume":"13","author":"Berry","year":"2016","journal-title":"Clin Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib33","doi-asserted-by":"crossref","first-page":"k698","DOI":"10.1136\/bmj.k698","article-title":"Key design considerations for adaptive clinical trials: a primer for clinicians","volume":"360","author":"Thorlund","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/CLEP.S156708","article-title":"Critical concepts in adaptive clinical trials","volume":"10","author":"Park","year":"2018","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib37","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib38","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3747\/co.22.2119","article-title":"Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis","volume":"22","author":"Beauchemin","year":"2015","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib39","first-page":"1035","article-title":"Relationship between OS and PFS in metastatic breast cancer (MBC): review of FDA submission data","volume":"29","author":"Cortazar","year":"2011"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib40","doi-asserted-by":"crossref","first-page":"e180416","DOI":"10.1001\/jamanetworkopen.2018.0416","article-title":"A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and differences in effect sizes","volume":"1","author":"Gyawali","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4155\/cli.15.14","article-title":"Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials","volume":"5","author":"Hummel","year":"2015","journal-title":"Clin Invest"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials","volume":"5","author":"Berry","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1740774514531352","article-title":"The utility of Bayesian predictive probabilities for interim monitoring of clinical trials","volume":"11","author":"Saville","year":"2014","journal-title":"Clin Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib44","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/sim.2151","article-title":"A review of methods for futility stopping based on conditional power","volume":"24","author":"Lachin","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.12688\/gatesopenres.12912.2","article-title":"Highly Efficient Clinical Trials Simulator (HECT): Software application for planning and simulating platform adaptive trials","volume":"3","author":"Thorlund","year":"2019","journal-title":"Gates Open Res"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.conctc.2017.11.001","article-title":"Bayesian adaptive clinical trials of combination treatments","volume":"8","author":"Thorlund","year":"2017","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib48","first-page":"56","article-title":"Journal reading patterns and preferences of pediatricians","volume":"95","author":"Tenopir","year":"2007","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib49","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2020.04.025_bib50","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12916-018-1196-2","article-title":"Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design","volume":"16","author":"Dimairo","year":"2018","journal-title":"BMC Med"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435619309874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435619309874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:16:59Z","timestamp":1760246219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435619309874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":49,"alternative-id":["S0895435619309874"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2020.04.025","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of platform trials with a checklist for clinical readers","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2020.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}